Filing Flows

Filing Flows › 8-K events › Citius Pharmaceuticals

Citius Pharmaceuticals: other events

Form 8-K filed Nov 4, 2026 · items 8.01

FDA decisionsCitius Oncology’s Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe

What the filing says

Citius Oncology’s Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe Data featured in oral presentation at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour G

Read the filing on SEC EDGAR →

What usually followsAcross 44,881 8-Ks reporting Item 8.01 (other events) in our universe, the stock's median move the next session was +0.1% (typical size ±1.5%, up 52% of the time); over the following 21 sessions, +1.1%. Every item ranked →

Citius Pharmaceuticals at a glance

Latest quarterQ3 FY26
Revenue$1.5M
Operating margin-785.4%
IndustryPharmaceutical Preparations

Citius Pharmaceuticals, Q3 FY26: revenue $1.5M, operating margin -785.4%. The chart follows the revenue to costs, profit and cash.

Citius Pharmaceuticals: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent fda decisions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.